Biotech finance stayed active as companies pursued public-market entry and large strategic capital moves. ADARx Pharmaceuticals priced a $446.3 million IPO, expanding cash for its RNA-silencing pipeline as the company’s public debut signaled strong investor appetite for siRNA programs in ultra-rare disease. In parallel, other financing milestones underscored continued funding for new modalities and early-stage pipeline expansion. Remynd raised €3.5 million for its septin-targeting Alzheimer’s candidate, while Kasvu Therapeutics landed a €30 million series A to advance antidepressant-like small molecules that aim to retain therapeutic benefits without hallucinogenic effects. Novo Nordisk’s continued deal-making also pointed to sustained capital flows into drug-delivery and formulation capabilities, with a large licensing commitment tied to longer-acting peptide platforms. For biotech operators, the financing signal remains consistent: investors are rewarding platform differentiation—particularly RNA therapeutics, CNS programs, and delivery technologies—rather than waiting for late-stage readouts.